 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /sɛfˈtæzɪdiːm/ |
| Trade names | Fortaz, Tazicef, others [1] |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a686007 |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | Intravenous, intramuscular, inhalation |
| Drug class | Antibiotic ( 3rd-generation cephalosporin) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 91% ( IM) |
| Metabolism | negligible |
| Elimination half-life | 1.6–2 hours |
| Excretion | 90–96% kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H22N6O7S2 |
| Molar mass | 546.57 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
 
(what is this?)
(verify) | |
Ceftazidime, sold under the brand names Fortaz among others, is an antibiotic useful for the treatment of a number of bacterial infections. [1] Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection. [1] It is given by injection into a vein, muscle, or eye. [1] [3]
Common side effects include nausea, allergic reactions, and pain at the site of injection. [1] Other side effects may include Clostridium difficile diarrhea. [1] It is not recommended in people who have had previous anaphylaxis to a penicillin. [1] Its use is relatively safe during pregnancy and breastfeeding. [4] It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall. [1]
Ceftazidime was patented in 1978 and came into commercial use in 1984. [5] It is on the World Health Organization's List of Essential Medicines. [6] Ceftazidime is available as a generic medication. [1] The wholesale cost in the developing world is about US$3–17 per day. [7] In the United States a course of treatment costs $100–200. [4] In the UK, ten 2 gram vials costs the NHS around £180, as of 2021. [8]
- ^ a b c d e f g h i j k "Ceftazidime". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
-
^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Archived from the original on 5 March 2021. Retrieved 12 January 2020.
- ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 87. ISBN 9781284057560.
- ^ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 495. ISBN 9783527607495. Archived from the original on 2016-12-20.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Ceftazidime". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
-
^ "5. Infection".
British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 561–562.
ISBN
978-0-85711-413-6.
{{ cite book}}: CS1 maint: date format ( link)
|
| |
|
| |
| Clinical data | |
|---|---|
| Pronunciation | /sɛfˈtæzɪdiːm/ |
| Trade names | Fortaz, Tazicef, others [1] |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a686007 |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | Intravenous, intramuscular, inhalation |
| Drug class | Antibiotic ( 3rd-generation cephalosporin) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 91% ( IM) |
| Metabolism | negligible |
| Elimination half-life | 1.6–2 hours |
| Excretion | 90–96% kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H22N6O7S2 |
| Molar mass | 546.57 g·mol−1 |
| 3D model ( JSmol) | |
| |
| |
|
(what is this?)
(verify) | |
Ceftazidime, sold under the brand names Fortaz among others, is an antibiotic useful for the treatment of a number of bacterial infections. [1] Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection. [1] It is given by injection into a vein, muscle, or eye. [1] [3]
Common side effects include nausea, allergic reactions, and pain at the site of injection. [1] Other side effects may include Clostridium difficile diarrhea. [1] It is not recommended in people who have had previous anaphylaxis to a penicillin. [1] Its use is relatively safe during pregnancy and breastfeeding. [4] It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall. [1]
Ceftazidime was patented in 1978 and came into commercial use in 1984. [5] It is on the World Health Organization's List of Essential Medicines. [6] Ceftazidime is available as a generic medication. [1] The wholesale cost in the developing world is about US$3–17 per day. [7] In the United States a course of treatment costs $100–200. [4] In the UK, ten 2 gram vials costs the NHS around £180, as of 2021. [8]
- ^ a b c d e f g h i j k "Ceftazidime". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
-
^ Cite error: The named reference
whowas invoked but never defined (see the help page). - ^ "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Archived from the original on 5 March 2021. Retrieved 12 January 2020.
- ^ a b Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 87. ISBN 9781284057560.
- ^ Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 495. ISBN 9783527607495. Archived from the original on 2016-12-20.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ "Ceftazidime". International Drug Price Indicator Guide. Archived from the original on 22 January 2018. Retrieved 8 December 2016.
-
^ "5. Infection".
British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. pp. 561–562.
ISBN
978-0-85711-413-6.
{{ cite book}}: CS1 maint: date format ( link)